1) 日本肺癌学会 : 肺癌患者におけるEGFR遺伝子変異検査の手引き第3.05版. 2016
2) Mok TS, Wu Y-L, Ahn M-J, et al : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 376 : 629─640, 2017
3) Soria JC, Ohe Y, Vansteenkiste J, et al : Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 378 : 113─125, 2018
4) 日本肺癌学会 : 肺癌患者におけるALK融合遺伝子検査の手引き第2.1版. 2015
5) 日本肺癌学会 : 肺癌患者におけるROS1融合遺伝子検査の手引き第1.0版. 2017
6) 日本肺癌学会 : 肺癌患者におけるBRAF遺伝子変異検査の手引き第1.0版. 2018
7) Kohno T : Implementation of “clinical sequencing” in cancer genome medicine in Japan. Cancer Sci 109 : 507─512, 2018
8) Zehir A, Benayed R, Shah RH, et al : Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23 : 703─713, 2017
9) Kou T, Kanai M, Yamamoto Y, et al : Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors. Cancer Sci 108 : 1440─1446, 2017
10) Steuer CE and Ramalingam SS : Tumor Mutation Burden : Leading Immunotherapy to the Era of Precision Medicine? J Clin Oncol 36 : 631─632, 2018
11) Schrader KA, Cheng DT, Joseph V, et al : Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol 2 : 104─111, 2016
12) Presley CJ, Tang D, Soulos PR, et al : Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting. JAMA 320 : 469─477, 2018
13) Bunn PA Jr and Aisner DL : Broad-Based Molecular Testing for Lung Cancer : Precisely the Time for Precision. JAMA 320 : 445─446, 2018